Literature DB >> 12409418

Rapid assessment of phenotypic resistance to protease inhibitors in human immunodeficiency virus type 1 group O.

Berta Rodés1, Eva Poveda, Vincent Soriano.   

Abstract

A bacteriophage lambda-based method was used to investigate the development of resistance to protease inhibitors (PI) in one subject infected with human immunodeficiency virus (HIV) type 1 group O who underwent multiple treatment regimens over a period of 4 years. A reduction in the susceptibility to indinavir of 6-fold and a reduction in the susceptibility to saquinavir of 24-fold were recognized after long exposure to these drugs with respect to baseline. The emergence of PI resistance corresponded to the selection of amino acid changes L10V, G48M, F53L, I54V, and L90M at the protease. The results were concordant with those obtained by a drug susceptibility assay with primary HIV isolates.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12409418      PMCID: PMC139640          DOI: 10.1128/JCM.40.11.4313-4316.2002

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  14 in total

1.  Naturally occurring sequence polymorphisms within HIV type 1 group O protease.

Authors:  K C Luk; L Kaptué; L Zekeng; V Soriano; L Gürtler; S G Devare; G Schochetman; J Hackett
Journal:  AIDS Res Hum Retroviruses       Date:  2001-11-01       Impact factor: 2.205

2.  Natural residues versus antiretroviral drug-selected mutations in HIV type 1 group O reverse transcriptase and protease related to virological drug failure in vivo.

Authors:  M P de Baar; W Janssens; A de Ronde; K Fransen; R Colebunders; L Kestens; G van der Groen; J Goudsmit
Journal:  AIDS Res Hum Retroviruses       Date:  2000-09-20       Impact factor: 2.205

3.  Characterization of the reverse transcriptase of a human immunodeficiency virus type 1 group O isolate.

Authors:  M E Quiñones-Mateu; V Soriano; E Domingo; L Menéndez-Arias
Journal:  Virology       Date:  1997-09-29       Impact factor: 3.616

4.  Susceptibility of human immunodeficiency virus type 1 group O isolates to antiretroviral agents: in vitro phenotypic and genotypic analyses.

Authors:  D Descamps; G Collin; F Letourneur; C Apetrei; F Damond; I Loussert-Ajaka; F Simon; S Saragosti; F Brun-Vézinet
Journal:  J Virol       Date:  1997-11       Impact factor: 5.103

5.  The Genetic Basis of HIV-1 Resistance to Reverse Transcriptase and Protease Inhibitors.

Authors:  Robert W Shafer; Rami Kantor; Matthew J Gonzales
Journal:  AIDS Rev       Date:  2000       Impact factor: 2.500

6.  A genetic screen for the isolation and characterization of site-specific proteases.

Authors:  H J Sices; T M Kristie
Journal:  Proc Natl Acad Sci U S A       Date:  1998-03-17       Impact factor: 11.205

7.  Isolation and envelope sequence of a highly divergent HIV-1 isolate: definition of a new HIV-1 group.

Authors:  P Charneau; A M Borman; C Quillent; D Guétard; S Chamaret; J Cohen; G Rémy; L Montagnier; F Clavel
Journal:  Virology       Date:  1994-11-15       Impact factor: 3.616

Review 8.  Group O human immunodeficiency virus-1 infections.

Authors:  H W Jaffe; G Schochetman
Journal:  Infect Dis Clin North Am       Date:  1998-03       Impact factor: 5.982

9.  Monitoring the response to antiretroviral therapy in HIV-1 group O infected patients using two new RT-PCR assays.

Authors:  C de Mendoza; W Lu; A Machuca; M Sainz; J Castilla; V Soriano
Journal:  J Med Virol       Date:  2001-07       Impact factor: 2.327

10.  Analysis of pol gene heterogeneity, viral quasispecies, and drug resistance in individuals infected with group O strains of human immunodeficiency virus type 1.

Authors:  M E Quiñones-Mateu; J L Albright; A Mas; V Soriano; E J Arts
Journal:  J Virol       Date:  1998-11       Impact factor: 5.103

View more
  1 in total

1.  HIV-1 Group O Genotypes and Phenotypes: Relationship to Fitness and Susceptibility to Antiretroviral Drugs.

Authors:  Denis M Tebit; Hamish Patel; Annette Ratcliff; Elodie Alessandri; Joseph Liu; Crystal Carpenter; Jean-Christophe Plantier; Eric J Arts
Journal:  AIDS Res Hum Retroviruses       Date:  2016-03-16       Impact factor: 2.205

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.